BioNTech Q4 GAAP EPS $2.04 Misses $2.64 Estimate, Sales $1.59B Miss $1.99B Estimate
Portfolio Pulse from Benzinga Newsdesk
BioNTech (NASDAQ:BNTX) reported Q4 GAAP EPS of $2.04, missing the $2.64 estimate, and sales of $1.59B, below the $1.99B estimate. This represents a significant decrease from the previous year, with earnings down 78.36% and sales down 63.54%.
March 20, 2024 | 10:16 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioNTech's Q4 earnings and sales significantly missed analyst estimates, with a dramatic decrease compared to last year's figures.
Missing both earnings and sales estimates significantly, especially with such a steep year-over-year decline, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100